Company intelligence / Profile preview

Ironshore Pharmaceuticals

Camana Bay, Cayman Islands

Ownership: Private
Development stage: Commercial

Overview

Ironshore's lead product JORNAY PM (methylphenidate HCl) is FDA-approved for ADHD in patients 6 years and older. It's the first evening-dosed methylphenidate product with a unique delayed and extended-release formulation that provides symptom control from wake-up through the evening.

Therapeutic areas: GastroenterologyPsychiatry
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

methylphenidate

Commercial

Indications: Attention deficit hyperactivity disorder (ADHD)

Partnerships

Knight Therapeutics

Beyond the preview

Go deeper on Ironshore Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ironshore Pharmaceuticals.

Explore the full profile